Results 31 to 40 of about 9,664,759 (367)
Relation of neuropathology with cognitive decline among older persons without dementia
Frontiers in Aging Neuroscience, 2013 Objective: Although it is now widely accepted that dementia has a long preclinical phase during which neuropathology accumulates and cognition declines, little is known about the relation of neuropathology with the longitudinal rate of change in ...
Patricia eBoyle +4 more
doaj +1 more source
Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative. [PDF]
, 2018 IntroductionWe characterize long-term disease dynamics from cognitively healthy to dementia using data from the Alzheimer's Disease Neuroimaging Initiative.MethodsWe apply a latent time joint mixed-effects model to 16 cognitive, functional, biomarker ...
Aisen, Paul S +5 more
core +1 more source
The amyloid hypothesis of Alzheimer's disease at 25 years
EMBO Molecular Medicine, 2016 Despite continuing debate about the amyloid β‐protein (or Aβ hypothesis, new lines of evidence from laboratories and clinics worldwide support the concept that an imbalance between production and clearance of Aβ42 and related Aβ peptides is a very early,
D. Selkoe, J. Hardy
semanticscholar +1 more source
Biomedicines, 2023 The role of metals in the pathogenesis of Alzheimer’s disease (AD) is still debated. Although previous research has linked changes in essential metal homeostasis and exposure to environmental heavy metals to the pathogenesis of AD, more research is needed to determine the relationship between metals and AD.
Mirjana Babić Leko +5 more
openaire +4 more sources
Risk Aversion is Associated with Decision Making among Community-Based Older Persons
Frontiers in Psychology, 2012 Background: Risk aversion is associated with many important decisions among younger and middle aged persons, but the association of risk aversion and decision making has not been well studied among older persons who face some of the most significant ...
Patricia eBoyle +3 more
doaj +1 more source
ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2023 INTRODUCTION Lecanemab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with activity at amyloid plaques.
Lawrence S. Honig +8 more
doaj +1 more source
NETosis in Alzheimer’s Disease [PDF]
Frontiers in Immunology, 2017 Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the progressive deterioration of cognitive functions. Its neuropathological features include amyloid-β (Aβ) accumulation, the formation of neurofibrillary tangles, and the loss of neurons and synapses.
Pietronigro, Enrica Caterina +3 more
openaire +4 more sources
Inference of RNA decay rate from transcriptional profiling highlights the regulatory programs of Alzheimer's disease. [PDF]
, 2017 The abundance of mRNA is mainly determined by the rates of RNA transcription and decay. Here, we present a method for unbiased estimation of differential mRNA decay rate from RNA-sequencing data by modeling the kinetics of mRNA metabolism.
Alkallas, Rached +3 more
core +3 more sources
Microbes and Alzheimer’s Disease
Journal of Alzheimer's Disease, 2016 descripción no proporcionada por ...
Judith A. Whittum-Hudson +33 more
openaire +11 more sources
On the reconceptualization of Alzheimer’s disease [PDF]
Bioethics, 2018 AbstractIn the hope of future treatments to prevent or slow down the disease, there is a strong movement towards an ever‐earlier detection of Alzheimer’s disease (AD). In conjunction with scientific developments, this has prompted a reconceptualization of AD, as a slowly progressive pathological process with a long asymptomatic phase. New concepts such
Maartje H. N. Schermer, Edo Richard
openaire +6 more sources